Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

EHA 2022 | Updates from the MonumenTAL-1 trial

Monique Minnema • 11 Jun 2022
EHA 2022
Multiple Myeloma Antibodies Talquetamab Tocilizumab
MonumenTAL-1

Monique Minnema, MD, PhD, University Medical Center Utrecht, Utrecht, Netherlands, shares some updates from the Phase I MonumenTAL-1 trial (NCT04634552) evaluating the safety and efficacy of talquetamab at two recommended doses in patients with relapsed/refractory (R/R) multiple myeloma. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.

More from Monique Minnema

Bing-Neel syndrome: a rare form of Waldenström’s macroglobulinemia
2:25
Bing-Neel syndrome: a rare form of Waldenström’s macroglobulinemia
Monique Minnema • 13 Nov 2024
Treating Bing-Neel syndrome: chemotherapy and BTK inhibitors
4:20
Treating Bing-Neel syndrome: chemotherapy and BTK inhibitors
Monique Minnema • 13 Nov 2024
Diagnosing Bing-Neel syndrome using MRI and lumbar puncture
1:27
Diagnosing Bing-Neel syndrome using MRI and lumbar puncture
Monique Minnema • 13 Nov 2024
Advice for physicians when managing bispecific antibody treatment for patients with myeloma
0:47
Advice for physicians when managing bispecific antibody treatment for patients with myeloma
Monique Minnema • 2 Jun 2024

Related Videos

Updated results from the iMMagine-1 trial of anito-cel in R/R multiple myeloma
4:32
Updated results from the iMMagine-1 trial of anito-cel in R/R multiple myeloma
Monique Minnema • 18 Dec 2025
Investigating AZD0120, a dual-targeting CAR-T product, in R/R myeloma: DURGA-1 preliminary results
3:36
Investigating AZD0120, a dual-targeting CAR-T product, in R/R myeloma: DURGA-1 preliminary results
Monique Minnema • 7 Dec 2025
A Phase II trial investigating IberKDd in R/R multiple myeloma: the ReKInDLE study
3:11
A Phase II trial investigating IberKDd in R/R multiple myeloma: the ReKInDLE study
Monique Minnema • 7 Dec 2025
Remote therapeutic monitoring reduces infection-related hospitalizations in hematologic cancers
4:04
Remote therapeutic monitoring reduces infection-related hospitalizations in hematologic cancers
Monique Minnema • 15 Dec 2025
The content of VJHemOnc is intended for healthcare professionals